Straits Times Index
3,303.58 +10.65 (+0.32%) Nikkei
38,236.07 -38.03 (-0.10%) Hang Seng
18,436.48 -39.44 (-0.21%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
64,074.27 +706.74 (+1.12%) CMC Crypto 200
1,333.89 +56.91 (+4.46%)
CG Oncology, Inc. (CGON)
After hours:
| Previous close | 39.50 |
| Open | 40.25 |
| Bid | 36.11 x 100 |
| Ask | 36.38 x 200 |
| Day's range | 30.22 - 46.99 |
| 52-week range | 28.55 - 50.23 |
| Volume | |
| Avg. volume | 556,878 |
| Market cap | 2.417B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 66.80 |
GlobeNewswireCretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus
- GlobeNewswire
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
Company to host virtual investor event on Friday, May 3, 2024, at 4:30pm EDT following presentation of results from the Phase 3 BOND-003 trial at the 2024 AUA Annual MeetingIRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, will host a virtual investor event on Friday, May 3, 2024, at 4:30pm
- GlobeNewswire
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
- Final results of CORE-001 Phase 2 trial of cretostimogene in combination with pembrolizumab for the treatment of BCG-unresponsive NMIBC -IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that an abstract with final results of CORE-001, its Phase 2 trial of cretostimogene in
